Skip to content

Noninvasive Imaging of Vulnerable Inflammatory Coronary Plaque using Cardiac PET/CT in Humans: a feasibility study

Noninvasive Imaging of Vulnerable Inflammatory Coronary Plaque using Cardiac PET/CT in Humans: a feasibility study - Imaging of coronary vulnerable inflammatory plaques

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON44976
Enrollment
24
Registered
2013-09-08
Start date
2016-07-29
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease unstable angina

Interventions

PET-tracer (11C-PK11195, 18F-AS101, or 18F-Galacto-RGD)

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Patients with an acute coronary syndrome and accompanying ECG abnormalities (unstable angina / non-ST-elevation myocardial infarction. * Clinical indication for invasive coronary angiography within 72 hours upon admission based on ESC guidelines pertaining treatment of patients with unstable angina or non-ST segment elevation myocardial infarction. * Age 35-75 years

Exclusion criteria

Exclusion criteria: * Prior percutaneous coronary intervention, coronary artery bypass surgery, or myocardial infarction * History of systemic inflammatory disease * Current cardiac arrhythmia * Renal failure with estimated glomerular filtration rate

Design outcomes

Primary

MeasureTime frame
This feasibility study will test different tracers for their feasibility to detect culprit lesions of patients with an ACS. Endpoints will be sufficient target to background uptake of tracer beyond 1.2 that coincides with the culprit lesion identified with general clinical information / CAG / OCT characteristics.

Secondary

MeasureTime frame
Kinetics of the three different PET tracers (11C-PK11195, 18F-AS101, or 18F-Galacto-RGD)

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)